ASM Microbe 2019 — Fixed-dose iclaprim infusion offers improved efficacy and safety


  • Emily Willingham, PhD
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Iclaprim as a fixed-dose 2-hour infusion outperforms weight-based dosing for efficacy and safety in patients with acute bacterial skin and skin structure infections (ABSSSIs).

Why this matters

  • This dihydrofolate reductase inhibitor is being used in a "broad range" of patients with ABSSSI or Gram-positive complicated skin and skin structure infections (cSSSIs), along with older age and comorbidities such as diabetes, according to results presented at ASM Microbe 2019.

Key results

  • Iclaprim in fixed-dose via 2-hour infusion showed improved minimum inhibitory concentration values that improved by 54% and 67% over values for the weight-based, 30-minute dose.
  • Maximum concentration values also improved, decreasing by 7.3%.

Study design

  • Data are from phase 3 REVIVE 1 and 2 studies of the fixed-dose regimen vs vancomycin compared with results from ASSIST 1 and 2 studies of the weight-based dose vs linezolid.

Limitations

  • These data were presented without peer review at a conference.